Advances and Challenges in Bioprocessing from a Design, Vendor and Manufacturing perspective

Venue: Engineers Ireland, 22 Clyde Road, Dublin 4 (free parking after 6.00pm) and live streaming to Jacobs Cork Office

Date: Thursday 20th October 2016

Time: 6.00pm to 9.00pm

Event Outline
6.00 PM – Registration

6.15 PM – Introduction – Denis McCarthy – Membership Director, Engineers Ireland

Facilitator

Brian Glennon  Chartered Engineer
Brian is Senior Director and co-founder of APC and Professor at the School of Chemical and Bioprocess Engineering at UCD.

Considerations in Process and Facility Design for Viral Safety – an End-User Perspective

Mammalian cell culture processes should be designed and operated to ensure no risk of viral contamination to the Patient. This talk will review some of the inherent risks involved, the technologies available to mitigate these risks and some considerations for the design and operation of cell culture facilities.

Mr Gerald Kierans - Technical Services Director, Pfizer Grange Castle
Gerald is the director responsible for Technical Services support for both commercial and clinical Drug Substance (cell culture, vaccine conjugation, bioprocess purification) and Drug Product manufacture (formulation & syringe filling) at the Grange Castle site.
Specialties: Facility design, technology development, bioprocess engineering, cell culture, filtration/chromatography/disposables technology, aseptic manufacture, automation & mechanical design, bioprocess development, process and cleaning validation, process control monitoring and improvement, sales & marketing, negotiation
Robustness and design considerations for Virus Filtration

Mathilde Bourguignat - Biomanufacturing Engineer with Merck
Mathilde’s role at Merck includes taking care of chromatography and column packing, as well as virus filtration and validation. She also helps customers implementing and developing chromatography and virus filtration processes at all scales, as well as performing troubleshooting and trainings.

Design Considerations for Viral Inactivation and Virus Filtration

The presentation will discuss some of the design factors relevant to selecting and sizing equipment for viral inactivation and for virus filtration. Viral inactivation of both media and of product streams will be examined. Pre and post viral segregation will be considered in relation to facility design.

John Levesley - Senior Process Engineer with PM Group
John has more than 18 years’ experience and specialises in design for bio-pharmaceuticals and fill finish. Recent projects include for Pfizer, Alexion, GSK and Novartis.

8.45 PM – 09:15 Q&A session
09:15 - Refreshments